Fibrocell Science, Inc. and Intrexon Corporation Expand Collaboration for Potential New Class of Therapeutics
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EXTON, Pa. & GERMANTOWN, Md.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, and Intrexon Corporation, a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) for development of a potentially new class of therapeutics.
Help employers find you! Check out all the jobs and post your resume.
EXTON, Pa. & GERMANTOWN, Md.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, and Intrexon Corporation, a leader in synthetic biology, announced today an expansion of their Exclusive Channel Collaboration (ECC) for development of a potentially new class of therapeutics.
Help employers find you! Check out all the jobs and post your resume.